Its receptor, EGFR, is often overexpressed and persistently activated in GBM, driving progression via pathways, including RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, Src kinases, and STAT transcription factors. This evidence concerns the gene MAP2K7 and glioblastoma.